Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Standard Biotools (LAB) Receivables - Net (2016 - 2026)

Standard Biotools has reported Receivables - Net over the past 16 years, most recently at $13.7 million for Q4 2025.

  • Quarterly Receivables - Net fell 6.96% to $13.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.7 million through Dec 2025, down 6.96% year-over-year, with the annual reading at $13.7 million for FY2025, 6.96% down from the prior year.
  • Receivables - Net was $13.7 million for Q4 2025 at Standard Biotools, down from $13.9 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $36.0 million in Q1 2024 and troughed at $10.9 million in Q2 2022.
  • The 5-year median for Receivables - Net is $15.5 million (2021), against an average of $19.3 million.
  • Year-over-year, Receivables - Net skyrocketed 148.29% in 2024 and then crashed 60.55% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $18.3 million in 2021, then dropped by 5.68% to $17.3 million in 2022, then increased by 15.58% to $20.0 million in 2023, then decreased by 26.19% to $14.7 million in 2024, then fell by 6.96% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Receivables - Net are $13.7 million (Q4 2025), $13.9 million (Q3 2025), and $14.6 million (Q2 2025).